ABSTRACT
Aims/Introduction
Glucagon is secreted from pancreatic α‐cells and plays an important role in amino acid metabolism in liver. Various animal models deficient in glucagon action show hyper‐amino acidemia and α‐cell hyperplasia, indicating that glucagon contributes to feedback regulation between the liver and the α‐cells. In addition, both insulin and various amino acids, including branched‐chain amino acids and alanine, participate in protein synthesis in skeletal muscle. However, the effect of hyperaminoacidemia on skeletal muscle has not been investigated. In the present study, we examined the effect of blockade of glucagon action on skeletal muscle using mice deficient in proglucagon‐derived peptides (GCGKO mice).
Materials and Methods
Muscles isolated from GCGKO and control mice were analyzed for their morphology, gene expression and metabolites.
Results
GCGKO mice showed muscle fiber hypertrophy, and a decreased ratio of type IIA and an increased ratio of type IIB fibers in the tibialis anterior. The expression levels of myosin heavy chain (Myh) 7, 2, 1 and myoglobin messenger ribonucleic acid were significantly lower in GCGKO mice than those in control mice in the tibialis anterior. GCGKO mice showed a significantly higher concentration of arginine, asparagine, serine and threonine in the quadriceps femoris muscles, and also alanine, aspartic acid, cysteine, glutamine, glycine and lysine, as well as four amino acids in gastrocnemius muscles.
Conclusions
These results show that hyperaminoacidemia induced by blockade of glucagon action in mice increases skeletal muscle weight and stimulates slow‐to‐fast transition in type II fibers of skeletal muscle, mimicking the phenotype of a high‐protein diet.
Keywords: Amino acid, Glucagon, Skeletal muscle
GCGKO mice have increased skeletal muscle weight and hypertrophy of muscle fibers.

INTRODUCTION
Glucagon is secreted from pancreatic α‐cells by stimulants, especially amino acids, and increases blood glucose levels by promoting glycolysis and gluconeogenesis in the liver 1 . In the process of gluconeogenesis in the liver, glucagon regulates expression levels of the gene‐encoding enzymes involved in amino acid metabolism 2 , 3 . Thus, glucagon is a hormone that regulates plasma amino acid levels, as well as blood glucose. Several animal models deficient in glucagon action have been established 4 , 5 , 6 , 7 , 8 . These models show lower blood glucose levels, superior glucose tolerance and hyperaminoacidemia due to the reduced conversion of amino acids to glucose in liver. In addition, among the various amino acids, glutamine, which show the highest plasma concentration in mice, contributes to α‐cell hyperplasia in the rodent defect in glucagon action 9 , 10 , 11 , 12 . These findings suggest that glucagon participates in an amino acid‐mediated inter‐organ network between the liver and pancreatic α‐cells. It is well‐known that both insulin and branched‐chain amino acids (BCAAs), especially leucine, play an important role in protein synthesis in skeletal muscle 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 . Recently, it has been reported that other amino acids, such as glutamine, glycine, and alanine, also are involved in skeletal muscle synthesis 21 , 22 , 23 , 24 , 25 . Furthermore, skeletal muscle is reported to be an important organ for its effect on glutamine stock, and glutamine metabolism regulates skeletal muscles synthesis 26 . However, the effect of glucagon deficiency‐induced hyperaminoacidemia on skeletal muscle has not been analyzed, because the glucagon receptor is not expressed in skeletal muscle 24 .
In the present study, we characterized the physiological and morphological features of skeletal muscle in mice deficient in the peptides derived from proglucagon, including glucagon and glucagon‐like peptide‐1 (GLP‐1; GCGKO) 27 , 28 , 29 , 30 , 31 , to address the role of glucagon in indirect regulation of skeletal muscle function through modification of amino acid metabolism.
MATERIALS AND METHODS
Experimental mice
All animal experimental procedures were carried out according to a protocol approved by the Institutional Animal Care and Use Committee of Fujita Health University.
GCGKO mice of the C57BL/6 background, in which the glucagon gene (Gcg) was replaced by a green fluorescent protein complementary deoxyribonucleic acid, were established and maintained as previously reported 27 . GCGKO male mice and Gcg heterozygous female mice were intercrossed to obtain male GCGKO and Gcg heterozygous mice to serve as controls, as previously described 28 , 29 , 30 , 31 . The mice were housed under a standard 12:12‐h light/dark cycle with free access to food and water. The experiments were carried out using 13‐week‐old GCGKO and Gcg heterozygous (control) male mice.
Plasma biochemical analyses
Blood was collected from the tip of the tail, and blood glucose levels were measured by an Antsense Duo Small Electrode Glucose Analyzer (Horiba, Kyoto, Japan). Blood samples were centrifuged (2,000 g, 15 min, 4°C) and the collected plasma samples were stored at −80°C until analysis. Plasma insulin levels were measured using a Mouse/Rat Insulin ELISA Kit (Morinaga Institute of Biological Science, Kanagawa, Japan), and plasma amino acid concentrations were measured by standard assays at SRL, Tokyo, Japan 28 , 31 .
Grip strength and exercise endurance test
The peak grip force was measured using a grip strength meter (Muromachi Kikai Co., Ltd, Tokyo, Japan), each mouse grasping a wire metal mesh was pulled away until grip was lost. Measurements were carried out five times for each mouse and maximum values were recorded 32 , 33 . During the exercise endurance test, running distance was calculated by running each mouse on a treadmill (MK‐680S treadmill; Muromachi Kikai Co., Ltd, Tokyo, Japan) at a speed of 10 m/min until exhaustion, which was determined by the mice withstanding three manual pushes on the electrical shocker plate 33 .
Analysis of subcutaneous and visceral fat mass by computed tomography scan
Mice were anesthetized with isoflurane (MSD Animal Health; Tokyo, Japan), fixed in a chamber and scanned using R_mCT2 (Rigaku Corporation, Tokyo, Japan). Subcutaneous and visceral fat mass were measured at the level of the two lumbar vertebrae above the ilium using metabolic analysis software for fat analysis. Subcutaneous and visceral fat area ratio was evaluated by computed tomography scan.
Analysis of immunohistochemistry of skeletal muscles
The mice were killed in the fed state. The collected skeletal muscle was rapidly frozen in isopentane cooled with liquid nitrogen. Serial sections from the tibialis anterior muscles were cut 10‐μm thick using a Microtome Cryostat (Leica Biosystems, Wetzlar, Germany) and placed on MAS‐coated slide glass. Specimens were blocked with protein‐block serum‐free reagent (Dako X0909; Dako, Glostrup, Denmark) for 5 min at room temperature and incubated overnight at 4°C with primary antibodies with rat monoclonal immunoglobulin G1 for Laminin α‐2 (4H8‐2; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), skeletal muscle myosin heavy chain IIA (SC‐71; Developmental Studies Hybridoma Bank, Iowa City, IA, USA) or skeletal muscle myosin heavy chain IIB (BF‐F3; Developmental Studies Hybridoma Bank), followed by 60‐min incubation in Alexa Fluor‐conjugated secondary antibody against goat anti‐rat immunoglobulin G1 (1:1,000; Alexa Fluor 594; Invitrogen, Waltham, MA, USA), goat anti‐mouse immunoglobulin G1 (1:500; Alexa Fluor 488; BioLegend, San Diego, CA, USA) and goat anti‐mouse immunoglobulin M (1:500; TRITC; SouthernBiotech, Birmingham, AL, USA) at room temperature. Images were captured using BZ‐9000 fluorescent microscope system (KEYENCE, Osaka, Japan). A cross‐sectional area (μm2) of muscle fibers and selected fields on muscle sections were measured using BZ2 analysis application (KEYENCE).
Amino acid measurements in skeletal muscles
The metabolites were extracted from muscle samples (approximately 20 mg), as previously reported 34 ; the metabolites were analyzed with high‐performance liquid chromatography–tandem mass spectrometry (LCMS‐8060; Shimadzu, Kyoto, Japan) using multiple reaction monitoring mode of tandem mass spectrometry 34 .
Isolation of tissue ribonucleic acid and polymerase chain reaction analysis of various tissue
Liver, white adipose tissue, brown adipose tissue and skeletal muscle tissues were collected. Extraction of ribonucleic acid (RNA) and synthesis of complementary deoxyribonucleic acid was carried out, as previously reported 31 . To characterize expression of glucagon receptor messenger RNA (mRNA), end‐products of 35‐cycle polymerase chain reaction were analyzed by electrophoresis with ethidium bromide staining. Quantitative real‐time reverse transcription polymerase chain reaction was carried out using the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). The primer sequences are shown in Table 1. The expression levels of mRNA of the genes of interest were normalized by those of β‐actin; those in GCGKO mice are shown relative to control mice.
Table 1.
Primers used for quantitative real‐time polymerase chain reaction
| Gene | Forward primers (5′–3′) | Reverse primers (5′–3′) |
|---|---|---|
| Myod1 | CCACTCCGGGACATAGACTTG | AAAAGCGCAGGTCTGGTGAG |
| IGF‐1 | TGGATGCTCTTCAGTTCGTG | GTCTTGGGCATGTCAGTGTG |
| MuRF1 | GTGTGAGGTGCCTACTTGCTC | GCTCAGTCTTCTGTCCTTGGA |
| Atrogin | ACAAAGGAAGTACGAAGGAGCG | GGCAGTCGAGAAGTCCAGTC |
| IL‐6 | CTTCACAAGTCGGAGGCTTA | TGCAAGTGCATCATCGTTGT |
| Myh7 | ACAAGCTGCAGCTGAAGGTG | TCATTCAGGCCCTTGGCAC |
| Myh2 | ACTTTGGCACTACGGGGAAAC | CAGCAGCATTTCGATCAGCTC |
| Myh1 | CTCTTCCCGCTTTGGTAAGTT | CAGGAGCATTTCGATTAGATCCG |
| Myh4 | CTTTGCTTACGTCAGTCAAGGT | AGCGCCTGTGAGCTTGTAAA |
| PGC‐1α | AAGTGGTGTAGCGACCAATCG | AATGAGGGCAATCCGTCTTCA |
| Myoglobin | CTGTTTAAGACTCACCCTGAGAC | GGTGCAACCATGCTTCTTCA |
| Tat | CCGAGCCATTGTGGACAACAT | GTTGACCACGAGACAAGCTGTTT |
| Sds | CAGCTTCCATGCTGCCATCAAG | CCTCCTGGTCTGAGATGACCTC |
| Got | TTGGTCTCACATCACTGAGCA | GATGGAGGTAGCGACGTAATCTAG |
| Gls2 | CGTCCGGTACTACCTCGGT | TGTCCCTCTGCAATAGTGTAGAA |
| Gpt | TCCAGGCTTCAAGGAATGGAC | CAAGGCACGTTGCACGATG |
| Gpt2 | AACCATTCACTGAGGTAATCCGA | GGGCTGTTTAGTAGGTTTGGGTA |
| β‐Actin | CATCCGTAAAGACCTCTATGCCAAC | ATGGAGCCACCGATCCACA |
Immunoblotting analysis
Immunoblotting analysis was carried out as previously described 35 using an anti‐phospho Akt antibody (1:2,000; #4060; Cell Signaling Technology, Waltham, MA, USA) or glyceraldehyde 3‐phosphate dehydrogenase antibody (1:4,000; #2118; Cell Signaling Technology). The quantification was carried out with ImageJ software (National Institutes of Health, Bethesda, MD, USA). Phosphorylation was expressed as percent phospho‐AKT relative to glyceraldehyde 3‐phosphate dehydrogenase; the values in GCGKO mice are shown relative to control mice.
Statistical analysis
All results are expressed as the mean ± standard error of the mean. Statistical analysis of comparison of means between the two groups was carried out using unpaired Student's t‐test. P‐values <0.05 were considered statistically significant between two groups. GraphPad Prism 9 for Windows (GraphPad Software, San Diego, CA, USA) was used for statistical data analysis.
RESULTS
Tissue weight and body composition in control and GCGKO mice
Bodyweight was significantly greater in GCGKO mice than that in control mice (Figure 1a), as previously reported 27 . Liver weight in GCGKO mice was also greater than that in control mice (Figure 1b), whereas white adipose tissue (inguinal and testes) and brown adipose tissue weight did not differ between the two groups (Figure 1c). The weight of hindlimb skeletal muscle tissues (tibialis anterior, extensor digitorum longus, soleus, gastrocnemius and quadriceps femoris) was then measured. Tibialis anterior muscle weight in GCGKO mice tended to be greater than that in control mice, and extensor digitorum longus, soleus, gastrocnemius and quadriceps femoris muscle weight was also significantly greater (Figure 1d). Subcutaneous fat area ratio in GCGKO mice tended to be less than that in control mice; visceral fat area ratio did not differ between control and GCGKO mice (Figure 1e–g). These results show that blockade of glucagon action increases the ratio of lean mass to adipose tissue mass, consistently with the previous finding in glucagon receptor‐deficient mice 7 .
Figure 1.

Tissue weight and body composition in control mice and mice deficient in proglucagon‐derived peptides (GCGKO). (a) Bodyweight, (b) liver weight, (c) white adipose tissue (WAT), brown adipose tissue (BAT) weight, and (d) skeletal muscle weight in control mice (black dots or bars; n = 7–8) and GCGKO mice (red dots or bars; n = 7–8). (e) Computed tomography scan in control mice and GCGKO mice; subcutaneous fat area (red), visceral fat area (yellow), (f) ratio of subcutaneous fat area to total area, (g) ratio of visceral fat area to total area in control mice (black dots; n = 7) and GCGKO mice (red dots; n = 7). **P < 0.01, ****P < 0.0001. Data are expressed as the mean ± standard error of the mean. EDL, extensor digitorum longus muscle; GS, gastrocnemius; QF, quadriceps femoris; TA, tibialis anterior.
Amino acid levels in plasma and skeletal muscle in control and GCGKO mice
Plasma insulin levels were significantly lower in GCGKO mice than those in control mice, but with slightly elevated blood glucose levels (Figure 2a,b). Almost all of the plasma amino acids levels including BCAAs, such as valine, leucine and isoleucine, were higher in GCGKO mice than those in control mice (Figure 2c). These findings are consistent with our previous reports 28 . In contrast, differences in amino acid concentrations were less pronounced in skeletal muscles. In the quadriceps femoris, only the four amino acids – arginine, asparagine, serine and threonine – showed significantly higher concentration in the GCGKO mice (Figure 2d). In gastrocnemius muscle, which consists predominantly of fast muscle fibers, alanine, aspartic acid, cysteine, glutamine, glycine and lysine, in addition to the forementioned four amino acids, showed a higher concentration in the GCGKO mice than those in control mice (Figure 2e).
Figure 2.

Blood glucose, plasma insulin, plasma amino acid and relative amino acids contents in skeletal muscles in control mice and mice deficient in proglucagon‐derived peptides (GCGKO) . (a) Blood glucose, (b) plasma insulin, and (c) plasma amino acids levels in control mice (black bars or dots; n = 8) and GCGKO mice (red bars or dots; n = 8). Amino acids contents (d) in quadriceps femoris muscle and (e) in gastrocnemius muscle of GCGKO mice (red bars; n = 5) relative to those in control mice (black bars; n = 5). *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001. Data are expressed as the mean ± standard error of the mean. Alanine (Ala), Arginine (Arg), Asparagine (Asn), Aspartic Acid (Asp), Cysteine (Cys), Glutamine (Gln), Glutamic Acid (Glu), Glycine (Gly), Histidine (His), Lysine (Lys), Methionine (Met), Phenylalanine (Phe), Proline (Pro), Serine (Ser), Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr), Isoleucine (Ile), Leucine (Leu), Valine (Val).
Skeletal muscle function in control and GCGKO mice
Whether increased muscle weight in GCGKO mice resulted in changes of muscle function was then evaluated. There was no significant difference in grip strength (Figure 3a) or running distance during the exercise endurance test (Figure 3b,c) between GCGKO and control mice.
Figure 3.

Grip strength and exercise capacity in control mice and mice deficient in proglucagon‐derived peptides (GCGKO) mice. (a) Grip strength, (b) distance run and (c) distance of run corrected by bodyweight (BW) during the exercise. Endurance test in control mice (black dots; n = 7–9) and GCGKO mice (red dots; n = 7–10). Data are expressed as the mean ± standard error of the mean.
Morphological analyses of skeletal muscle in control and GCGKO mice
Muscle fiber size was assessed by immunostaining of tibialis anterior muscle for laminin α2 stain in the GCGKO and control mice (Figure 4a). The mean muscle fiber size and number of muscle fibers were not different between the control mice and GCGKO mice (Figure 4b,c). The frequency distribution of fiber areas showed that an increased percentage of larger fibers (shifted to the right side) in the tibialis anterior muscle was greater in GCGKO mice than that in control mice (Figure 4d). These results suggest that the increase in muscle mass in GCGKO mice can be attributed to the increase in large muscle fibers (Figure 4d). We then investigated the percentage of each fiber type in tibialis anterior muscle (Figure 4e). Interestingly, GCGKO mice showed a decrease in type IIA fiber composition, which consists predominantly of slow‐twitch muscle fibers, and an increase in type IIB fiber composition, which consists predominantly of fast‐twitch muscle fibers in the tibialis anterior muscle compared with those in control mice (Figure 4f). These results suggest that a slow‐to‐fast transition in type II fibers occurred in the tibialis anterior muscle in GCGKO mice.
Figure 4.

Characterization of skeletal muscle in control mice and mice deficient in proglucagon‐derived peptides (GCGKO). (a) Immunostaining of the tibialis anterior muscle for laminin α2 (red) in control and GCGKO mice. (b) Fiber size and (c) fiber count of tibialis anterior muscle in control mice (black bars; n = 5) and GCGKO mice (red bars; n = 5). (d) Frequency distribution of fiber cross‐section area of the tibialis anterior muscle in control mice (black bars; n = 5) and GCGKO mice (red bars; n = 5). (e) Immunostaining of each muscle fiber type in the tibialis anterior muscle (type IIA, green; type IIB, red; non‐type IIA, IIB [type IIX], black) in control and GCGKO mice. (f) Percentage of each fiber type in the tibialis anterior muscle in control mice (black bars; n = 5) and GCGKO mice (red bars; n = 5). *P < 0.05, **P < 0.01. Data are expressed as the mean ± standard error of the mean.
Gene expression levels in the liver and skeletal muscle in control and GCGKO mice
To further characterize muscle synthesis and degradation, and possible slow‐to‐fast transition in type II fibers, we analyzed gene expression in the tibialis anterior muscle. Local insulin‐like growth factor 1 (IGF‐1) production in skeletal muscle has been reported to contribute to the increase of muscle mass seen in rodent models having IGF‐1 overexpression 36 , 37 , 38 ; expression levels of IGF‐1 were significantly higher in GCGKO mice than those in control mice, which suggests an increase in muscle synthesis. In contrast, expression levels of muscle‐specific RING finger protein (MuRF1) and atrogin, which are involved in muscle degradation, did not differ between GCGKO mice and control mice (Figure 5a).
Figure 5.

Messenger ribonucleic acid (mRNA) expression patterns of Gcg receptor in various tissue and mRNA expression levels of each gene in the liver and skeletal muscle. (a) Myogenic differentiation 1 (Myod1), insulin‐like growth factor 1 (IGF‐1), muscle‐specific RING finger protein 1 (MuRF1), atrogin, interleukin‐6 (IL‐6), myosin heavy chain 7 (Myh7), myosin heavy chain 2 (Myh2), myosin heavy chain 1 (Myh1), myosin heavy chain 4 (Myh4), peroxisome proliferator‐activated receptor γ coactivator‐1α (PGC‐1α) and myoglobin in the tibialis anterior muscle in control mice (black bars; n = 6) and mice deficient in proglucagon‐derived peptides (GCGKO) (red bars; n = 6). (b) Gcg receptor in the liver, quadriceps femoris muscle, white adipose tissue (WAT) and brown adipose tissue (BAT) in C57BL/6 mice. (c) Tyrosine aminotransferase (Tat), serine dehydratase (Sds), glutamic‐oxaloacetic transaminase (Got), glutaminase 2 (Gls2), glutamic pyruvic transaminase (Gpt) and glutamic pyruvic transaminase 2 (Gpt2) in the liver in control mice (black bars; n = 8) and GCGKO mice (red bars; n = 8). *P < 0.05, **P < 0.01, ****P < 0.001. Data are expressed as the mean ± standard error of the mean.
Peroxisome proliferator‐activated receptor γ coactivator‐1α drives the formation of slow‐twitch muscle fibers and increases myoglobin expression 39 , 40 . In GCGKO mice, expression of myoglobin was significantly decreased with lower, although not significant, expression of peroxisome proliferator‐activated receptor γ coactivator‐1α. The expression levels of myosin heavy chain 7, 2 and 1, which are predominantly expressed in type I, IIa and IIx fibers, respectively 39 , were significantly decreased in GCGKO mice. These results are in accord with a slow‐to‐fast transition of type II fibers in the tibialis anterior in GCGKO mice, and suggest possible involvement of decreased peroxisome proliferator‐activated receptor γ coactivator‐1α expression.
To confirm that glucagon is not directly involved in the changes in muscle, we confirmed by polymerase chain reaction analyses that glucagon receptor mRNA was absent in skeletal muscle (Figure 5b). In contrast, expression of glucagon receptor in the liver, white adipose tissue and brown adipose tissue was readily detected (Figure 5b). In the liver, expression levels of serine dehydratase, glutamic‐oxaloacetic transaminase, glutaminase 2 and glutamic pyruvic transaminase (Gpt) were significantly lower in GCGKO mice than those in control mice (Figure 5c). These results are consistent with impaired amino acid metabolism and hyperaminoacidemia in GCGKO mice.
Phosphorylation of protein kinase B in tibialis anterior muscle in control and GCGKO mice
The IGF‐1–protein kinase B pathway plays an important role in skeletal muscle growth 41 . To address the increased IGF‐1 mRNA expression activation of intracellular signal in skeletal muscle, phosphorylation of protein kinase B in the tibialis anterior muscle of control and GCGKO mice was evaluated by western blotting analysis. Phosphorylation of protein kinase B in the tibialis anterior muscle tended to be increased in GCGKO mice compared with that in control mice (Figure 6).
Figure 6.

Quantification of protein kinase B (AKT) phosphorylation in the tibialis anterior muscle in control mice and mice deficient in proglucagon‐derived peptides (GCGKO) mice. Representative immunoblots and quantification of AKT phosphorylation in tibialis anterior muscle in mice fed ad libitum condition. AKT phosphorylation is expressed as the ratio of phospho‐AKT (pAKT) relative to glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) in control mice (black bars; n = 6) and GCGKO mice (red bars; n = 6). Data are expressed as the mean ± standard error of the mean.
DISCUSSION
Glucagon plays an important role in amino acid metabolism in the liver and regulates plasma amino acid levels 12 . We previously reported that a high‐protein diet (HPD) increases plasma glucagon levels in type 2 diabetes patients 42 . We have also reported that plasma glucagon levels and the expression levels of gene‐encoding enzymes involved in amino acid metabolism in the liver are strongly increased in mice fed a HPD for 7 days 31 . In mice fed a HPD, plasma concentrations of most amino acids levels are not significantly altered, except for those of BCAAs, which are increased more than twofold compared with those in mice fed a control diet 31 . These results suggest that glucagon promotes amino acid metabolism in the liver to maintain plasma amino acid levels in response to changes in protein intake. However, plasma BCAA levels are increased in response to increased intake, probably because BCAA is metabolized mainly in skeletal muscle, an organ in which the glucagon receptor is not expressed (Figure 5b) 24 . Increased intake of essential amino acids including BCAAs, such as leucine, stimulates muscle synthesis in elderly people 20 , 43 . In contrast, increased intake of non‐essential amino acids do not show such effect, probably due to increased glucagon secretion and amino acid catabolism in the liver. The effect of increased plasma non‐essential amino acid levels on skeletal muscle synthesis has, therefore, not been explored in detail. Interestingly, glucagon receptor‐deficient mice show increased lean mass 7 and hyperaminoacidemia 10 . In both GCGKO and glucagon receptor‐deficient mice, glucagon action is absent, and both show hyperamionoacidemia. However, these animal models show different GLP‐1 levels: they are increased in glucagon receptor‐deficient mice 7 , and absent in GCGKO mice. Thus, GCGKO mice provide an opportunity to analyze the effect of hyperaminoacidemia on skeletal muscle without the action of increased GLP‐1, which might have an anabolic effect 44 .
In the present study, we found that GCGKO mice showed increased skeletal muscle weight and an increased percentage of larger fibers with a decrease in type IIA fibers and an increase in type IIB fibers in the tibialis anterior muscle compared with that in controls, showing that glucagon deficiency promotes a slow‐to‐fast transition in type II fibers of skeletal muscle. Although the difference did not reach statistical significance, the fact that grip strength and exercise tolerance tended to be enhanced and weakened, respectively, in the GCGKO mice is consistent with a slow‐to‐fast transition of skeletal muscle fibers in GCGKO mice. In addition, we analyzed amino acid concentrations in skeletal muscle in addition to those of plasma, and showed that several amino acids in skeletal muscle are increased in GCGKO mice (Figure 2c–e).
It has recently been reported that glucagon stimulates Gpt activity in liver, which converts alanine to pyruvate to promote gluconeogenesis, and also decreases muscle mass and grip strength 24 , 25 . Furthermore, it has been shown that Gpt/Gpt2 silencing in the liver increases the alanine concentration in both plasma and skeletal muscle, resulting in increased muscle mass and grip strength in obese and/or type 2 diabetes mice, as they are in patients 24 . In accord with these findings, decreased expression levels of Gpt mRNA in the liver of GCGKO mice was found together with an increased alanine concentration in plasma and gastrocnemius muscle in the present study (Figures 2c,d and 5c).Thus, regulation of alanine metabolism by glucagon contributes not only to a liver–α‐cell axis 11 , but also to a liver–skeletal muscle axis, suggesting that blockade of glucagon action can be a potential target for maintaining muscle mass.
Mice fed HPD for 42 weeks 45 show increased muscle volume and fiber size with a slow‐to‐fast transition in type II fibers of skeletal muscle. The similar skeletal muscle phenotypes observed in GCGKO mice and HPD‐fed mice suggest that hyperaminoacidemia elicits an effect similar to that of intervention of long‐term HPD. Nevertheless, GCGKO mice differ from HPD‐fed mice in other aspects: mice fed HPD show weight loss accompanied by a remarkable reduction in adipose tissue due to the reduction of caloric intake 31 , 46 ; food intake 31 and adipose tissue weight are not decreased in GCGKO mice in comparison with control mice (Figure 1).
The relative contribution of glucagon excess and insulin insufficiency on hyperglycemia in diabetes patients has been matter of discussion 47 , 48 , 49 . Aging‐dependent decline in muscle strength and quality in the legs is reported to progress more rapidly in type 2 diabetes patients than in non‐diabetic individuals 50 . Skeletal muscle‐specific insulin receptor‐deficient mice show reduced muscle mass, size and grip strength 51 , 52 , suggesting that insufficient insulin action leads to decreased muscle protein synthesis 53 . Whether excessive glucagon secretion contributes to the declines in leg muscle function in elderly type 2 diabetes patients remains to be investigated in future studies.
A limitation of the present study is that we could not evaluate whether GLP‐1 and hormones, such as corticosterone and catecholamine, which might be affected by glucagon deficiency, participate in the increase in skeletal muscle weight or stimulate a slow‐to‐fast transition in type II fibers of skeletal muscle in GCGKO mice. Another limitation is that we could not determine whether glucagon deficiency protects against skeletal muscle loss using older GCGKO mice, because they had pancreatic neuroendocrine tumors with lung and liver metastasis 54 .
In conclusion, glucagon regulates plasma amino acid levels through amino acid metabolism in the liver and indirectly alters muscle mass in mice; glucagon blockade in mice deficient in proglucagon‐derived peptides mimics the phenotype of a HPD.
DISCLOSURE
The authors declare no conflict of interest.
Approval of the research protocol: The mouse experiments and the research protocol were approved by Institutional Animal Care and Use Committee of Fujita Health University (DP18015: approval date 29 November, 2018 and AP19006: approval date 22 February, 2019).
Informed Consent: N/A.
Registry and the registration no. of the study/trial: N/A.
Animal studies: N/A.
REFERENCES
- 1. Hædersdal S, Andersen A, Knop FK, et al. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. Nat Rev Endocrinol 2023; 19(6): 321–335. [DOI] [PubMed] [Google Scholar]
- 2. Hayashi Y. Glutaminostatin: Another facet of glucagon as a regulator of plasma amino acid concentrations. J Diabetes Investig 2019; 10: 1391–1393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Winther‐Sørensen M, Galsgaard KD, Santos A, et al. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. Mol Metab 2020; 42: 1–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Mu J, Jiang G, Brady E, et al. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon‐like peptide 1 without severe alpha cell hypertrophy in diet‐induced obese mice. Diabetologia 2011; 54: 2381–2391. [DOI] [PubMed] [Google Scholar]
- 5. Furuta M, Yano H, Zhou A, et al. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 1997; 94: 6646–6651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Gagnon J, Mayne J, Chen A, et al. PCSK2‐null mice exhibit delayed intestinal motility, reduced refeeding response and altered plasma levels of several regulatory peptides. Life Sci 2011; 88: 212–217. [DOI] [PubMed] [Google Scholar]
- 7. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 2003; 100: 1438–1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Sloop KW, Cao JXC, Siesky AM, et al. Michael, hepatic and glucagon‐like peptide‐1‐mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Investig 2004; 113: 1571–1581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Dean ED, Li M, Prasad N, et al. Interrupted glucagon signaling reveals hepatic α cell Axis and role for L‐glutamine in α cell proliferation. Cell Metab 2017; 25: 1362–1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Kim J, Okamoto H, Huang ZJ, et al. Amino acid transporter Slc38a5 controls glucagon receptor inhibition‐induced pancreatic α cell hyperplasia in mice. Cell Metab 2017; 25: 1348–1361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Wewer Albrechtsen NJ, Pedersen J, Galsgaard KD, et al. The liver‐α‐cell Axis and type 2 diabetes. Endocr Rev 2019; 40: 1353–1366. [DOI] [PubMed] [Google Scholar]
- 12. Hayashi Y, Seino Y. Regulation of amino acid metabolism and α‐cell proliferation by glucagon. J Diabetes Investig 2018; 9: 464–472. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Sreekumaran Nair K, Short KR, Baker DH, et al. Hormonal and signaling role of branched‐chain amino acids. J Nutr 2005; 135: 1547–1552. [DOI] [PubMed] [Google Scholar]
- 14. Kamei Y, Hatazawa Y, Uchitomi R, et al. Regulation of skeletal muscle function by amino acids. Nutrients 2020; 12: 261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Buse MG, Reid SS. Leucine. A possible regulator of protein turnover in muscle. J Clin Invest 1975; 56: 1250–1261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Garber AJ. Skeletal muscle protein and amino acid metabolism in experimental chronic uremia in the rat. Accelerated alanine and glutamine formation and release. J Clin Investig 1978; 62: 623–632. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Anthony JC, Yoshizawa F, Anthony TG, et al. Leucine stimulates translation initiation in skeletal muscle of Postabsorptive rats via a rapamycin‐sensitive pathway. J Nutr 2000; 130: 2413–2419. [DOI] [PubMed] [Google Scholar]
- 18. Anthony JC, Reiter AK, Anthony TG, et al. Orally administered leucine enhances protein synthesis in skeletal muscle of diabetic rats in the absence of increases in 4E‐BP1 or S6K1 phosphorylation. Diabetes 2002; 51: 928–936. [DOI] [PubMed] [Google Scholar]
- 19. Pennings B, Boirie Y, Senden JMG, et al. Whey protein stimulates postprandial muscle protein accretion more effectively than do casein and casein hydrolysate in older men. Am J Clin Nutr 2011; 93: 997–1005. [DOI] [PubMed] [Google Scholar]
- 20. Bukhari SS, Phillips BE, Wilkinson DJ, et al. Intake of low‐dose leucine‐rich essential amino acids stimulates muscle anabolism equivalently to bolus whey protein in older women at rest and after exercise. Am J Physiol Endocrinol Metab 2015; 308: 1056–1065. [DOI] [PubMed] [Google Scholar]
- 21. Girven M, Dugdale HF, Owens DJ, et al. l‐glutamine improves skeletal muscle cell differentiation and prevents myotube atrophy after cytokine (TNF‐α) stress via reduced p38 MAPK signal transduction. J Cell Physiol 2016; 231: 2720–2732. [DOI] [PubMed] [Google Scholar]
- 22. Amirato GR, Borges JO, Marques DL, et al. L‐glutamine supplementation enhances strength and power of knee muscles and improves glycemia control and plasma redox balance in exercising elderly women. Nutrients 2021; 13: 1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Ham DJ, Murphy KT, Chee A, et al. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Clin Nutr 2014; 33: 448–458. [DOI] [PubMed] [Google Scholar]
- 24. Okun JG, Rusu PM, Chan AY, et al. Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. Nat Metab 2021; 3: 394–409. [DOI] [PubMed] [Google Scholar]
- 25. Egami R, Kokaji T, Hatano A, et al. Trans‐omic analysis reveals obesity‐associated dysregulation of inter‐organ metabolic cycles between the liver and skeletal muscle. iScience 2021; 24: 102217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Cruzat V, Rogero MM, Keane KN, et al. Glutamine: Metabolism and immune function, supplementation and clinical translation. Nutrients 2018; 10: 1564. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Hayashi Y, Yamamoto M, Mizoguchi H, et al. Mice deficient for glucagon gene‐derived peptides display normoglycemia and hyperplasia of islet α‐cells but not of intestinal L‐cells. Mol Endocrinol 2009; 23: 1990–1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Watanabe C, Seino Y, Miyahira H, et al. Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon‐derived peptides. Diabetes 2012; 61: 74–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Fukami A, Seino Y, Ozaki N, et al. Ectopic expression of GIP in pancreatic β‐cells maintains enhanced insulin secretion in mice with complete absence of proglucagon‐derived peptides. Diabetes 2013; 62: 510–518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Iida A, Seino Y, Fukami A, et al. Endogenous GIP ameliorates impairment of insulin secretion in proglucagon‐deficient mice under moderate beta cell damage induced by streptozotocin. Diabetologia 2016; 59: 1533–1541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Ueno S, Seino Y, Hidaka S, et al. High protein diet feeding aggravates Hyperaminoacidemia in mice deficient in proglucagon‐derived peptides. Nutrients 2022; 14: 975. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Uezumi A, Ikemoto‐Uezumi M, Zhou H, et al. Mesenchymal Bmp3b expression maintains skeletal muscle integrity and decreases in age‐related sarcopenia. J Clin Investig 2021; 131: e139617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Ohsawa Y, Hagiwara H, Nakatani M, et al. Muscular atrophy of caveolin‐3‐deficient mice is rescued by myostatin inhibition. J Clin Investig 2006; 116: 2924–2934. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Sumitomo M, Takahara K, Zennami K, et al. Tryptophan 2,3‐dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma. Cancer Sci 2021; 112: 1038–1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Sakamoto E, Seino Y, Fukami A, et al. Ingestion of a moderate high‐sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon‐like peptide‐1 secretion. J Diabetes Investig 2012; 3: 432–440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Barton ER, Morris L, Musaro A, et al. Muscle‐specific expression of insulin‐like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002; 157: 137–148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Alzghoul MB, Gerrard D, Watkins BA, et al. Ectopic expression of IGF‐I and shh by skeletal muscle inhibits disuse‐mediated skeletal muscle atrophy and bone osteopenia in vivo. FASEB J 2004; 1: 221–223. [DOI] [PubMed] [Google Scholar]
- 38. Schertzer JD, Plant DR, Lynch GS. Optimizing plasmid‐based gene transfer for investigating skeletal muscle structure and function. Mol Ther 2006; 13: 795–803. [DOI] [PubMed] [Google Scholar]
- 39. Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev 2011; 91: 1447–1531. [DOI] [PubMed] [Google Scholar]
- 40. Lin J, Wu H, Tarr PT, et al. Transcriptional co‐activator PGC‐1 alpha drives the formation of slow‐twitch muscle fibres. Nature 2002; 418: 797–801. [DOI] [PubMed] [Google Scholar]
- 41. Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1‐Akt/PKB pathway: Insights from genetic models. Skelet Muscle 2011; 1: 4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Kondo‐Ando M, Seino Y, Morikawa R, et al. Low‐carbohydrate diet by staple change attenuates postprandial GIP and CPR levels in type 2 diabetes patients. J Diabetes Complications 2019; 33: 107415. [DOI] [PubMed] [Google Scholar]
- 43. Volpi E, Kobayashi H, Sheffield‐Moore M, et al. Essential amino acids are primarily responsible for the amino acid stimulation of muscle protein anabolism in healthy elderly adults. Am J Clin Nutri 2003; 78: 250–258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Abdulla H, Phillips BE, Wilkinson DJ, et al. Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. Aging Cell 2020; 19: e13202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Mitsuishi M, Miyashita K, Muraki A, et al. Dietary protein decreases exercise endurance through rapamycin‐sensitive suppression of muscle mitochondria. Am J Physiol Endocrinol Metab 2013; 305: 776–784. [DOI] [PubMed] [Google Scholar]
- 46. Mithieux G, Misery P, Magnan C, et al. Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. Cell Metab 2005; 2: 321–329. [DOI] [PubMed] [Google Scholar]
- 47. Seino Y, Kuwata H, Yabe D. Incretin‐based drugs for type 2 diabetes: Focus on east Asian perspectives. J Diabetes Investig 2016; 7: 102–109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J Clin Investig 2012; 122: 4–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Mitrakou A, Kelley D, Veneman T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381–1390. [DOI] [PubMed] [Google Scholar]
- 50. Seok WP, Goodpaster BH, Strotmeyer ES, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: The health, aging, and body composition study. Diabetes Care 2007; 30: 1507–1512. [DOI] [PubMed] [Google Scholar]
- 51. O'Neill BT, Lauritzen HPMM, Hirshman MF, et al. Differential role of insulin/IGF‐1 receptor signaling on muscle growth and glucose homeostasis. Cell Rep 2015; 11: 1220–1235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. O'Neill BT, Lee KY, Klaus K, et al. Insulin and IGF‐1 receptors regulate FoxO‐mediated signaling in muscle proteostasis. J Clin Investig 2016; 126: 3433–3446. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Bassil MS, Gougeon R. Muscle protein anabolism in type 2 diabetes. Curr Opin Clin Nutr Metab Care 2013; 16: 83–88. [DOI] [PubMed] [Google Scholar]
- 54. Takano Y, Ksai K, Kikumori T, et al. Pancreatic neuroendocrine tumors in mice deficient in proglucagon‐derived peptides. PLoS One 2015; 10: e0133812. [DOI] [PMC free article] [PubMed] [Google Scholar]
